Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $14.80

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) have received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $14.80.

A number of brokerages have issued reports on TNGX. Guggenheim increased their price objective on shares of Tango Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a report on Friday, February 6th. B. Riley Financial lifted their price target on shares of Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Stifel Nicolaus initiated coverage on shares of Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, Director Barbara Weber sold 30,519 shares of Tango Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the completion of the transaction, the director directly owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. This trade represents a 1.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Daniella Beckman sold 10,317 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the sale, the chief financial officer owned 184,297 shares in the company, valued at $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 59,288 shares of company stock valued at $726,871. 7.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors have recently modified their holdings of TNGX. Deutsche Bank AG raised its holdings in Tango Therapeutics by 25.5% during the 4th quarter. Deutsche Bank AG now owns 74,203 shares of the company’s stock valued at $657,000 after buying an additional 15,054 shares during the period. LPL Financial LLC bought a new stake in shares of Tango Therapeutics in the 4th quarter worth about $106,000. Franklin Resources Inc. boosted its stake in shares of Tango Therapeutics by 50.8% during the 4th quarter. Franklin Resources Inc. now owns 1,398,057 shares of the company’s stock worth $12,387,000 after purchasing an additional 471,153 shares during the period. Los Angeles Capital Management LLC grew its holdings in Tango Therapeutics by 273.8% during the 4th quarter. Los Angeles Capital Management LLC now owns 64,243 shares of the company’s stock valued at $569,000 after purchasing an additional 47,058 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Tango Therapeutics by 227.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company’s stock worth $43,790,000 after purchasing an additional 3,432,939 shares during the period. 78.99% of the stock is owned by institutional investors.

Tango Therapeutics Stock Down 0.6%

Shares of NASDAQ:TNGX opened at $12.61 on Monday. The stock has a market capitalization of $1.70 billion, a PE ratio of -13.56 and a beta of 1.75. The firm’s 50 day moving average price is $10.56 and its 200-day moving average price is $8.72. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $13.46.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.